Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy

被引：185

作者：

Arora, S. ^{[1
]}

Singh, S. ^{[1
]}

Piazza, G. A. ^{[1
,2
]}

Contreras, C. M. ^{[3
]}

Panyam, J. ^{[4
]}

Singh, A. P. ^{[1
,2
]}

机构：

[1] Univ S Alabama, Dept Oncol Sci, Mitchell Canc Inst, Mobile, AL 36604 USA

[2] Univ S Alabama, Coll Med, Dept Biochem & Mol Biochem, Mobile, AL 36604 USA

[3] Univ S Alabama, Coll Med, Dept Surg, Mobile, AL 36604 USA

[4] Univ Minnesota, Coll Pharm, Dept Pharmaceut, Minneapolis, MN 55455 USA

来源：

CURRENT MOLECULAR MEDICINE | 2012年 / 12卷 / 10期

关键词：

Honokiol; chemoprevention; chemotherapy; natural agent; COMBINING LIPOSOMAL HONOKIOL; MAGNOLIA BARK EXTRACT; NF-KAPPA-B; BREAST-CANCER; IN-VITRO; INHIBITS ANGIOGENESIS; NITRIC-OXIDE; APOPTOSIS; GROWTH; ACTIVATION;

D O I：

10.2174/156652412803833508

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Honokiol (3',5-di-(2-propenyl)-1,1'-biphenyl-2,4'-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappa B), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.

引用

页码：1244 / 1252

页数：9